Cargando…

Antituberculosis Drug Interactions with Membranes: A Biophysical Approach Applied to Bedaquiline

This work focuses on the interaction of the novel and representative antituberculosis (anti-TB) drug bedaquiline (BDQ) with different membrane models of eukaryotic and prokaryotic cells. The effect of BDQ on eukaryotic cell membrane models was assessed using liposomes, namely, multilamellar vesicles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinheiro, Marina, Amenitsch, Heinz, Reis, Salette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918463/ https://www.ncbi.nlm.nih.gov/pubmed/31671599 http://dx.doi.org/10.3390/membranes9110141

Ejemplares similares

Application of Chiral Transfer Reagents to Improve Stereoselectivity and Yields in the Synthesis of the Antituberculosis Drug Bedaquiline
por: Robey, Juliana M. S., et al.
Publicado: (2023)

Interpretation of the mechanism of action of antituberculosis drug bedaquiline based on a novel two‐ion theory of energy coupling in ATP synthesis
por: Nath, Sunil
Publicado: (2018)

3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel
por: Sutherland, Hamish S., et al.
Publicado: (2019)

Design and Stereochemical Research (DFT, ECD and Crystal Structure) of Novel Bedaquiline Analogs as Potent Antituberculosis Agents
por: Geng, Yiding, et al.
Publicado: (2016)

Acquired Resistance to Antituberculosis Drugs
por: Aung, Htin Lin, et al.
Publicado: (2018)

Antituberculosis drug-induced hepatotoxicity in children
por: Donald, Peter R
Publicado: (2011)

Diagnosis of Hypersensitivity Induced by Antituberculosis Drugs
por: Wu, Yuqing, et al.
Publicado: (2021)

Antituberculosis Targeted Drug Delivery as a Potential Future Treatment Approach
por: Mazlan, Mohd Khairul Nizam, et al.
Publicado: (2021)

Applied biophysics : a molecular approach for physical scientists /
por: Waigh, Tom A.
Publicado: (2007)

Biophysical Approaches for Applying and Measuring Biological Forces
por: Sun, Wenxu, et al.
Publicado: (2021)

Licofelone-DPPC Interactions: Putting Membrane Lipids on the Radar of Drug Development
por: Pereira-Leite, Catarina, et al.
Publicado: (2019)

Mycobacterium tuberculosis resistance to antituberculosis drugs in Mozambique,
por: Pires, Germano Manuel, et al.
Publicado: (2014)

P25 - Hypersensitivity/adverse reactions to antituberculosis drugs – a case report
por: Barrosa Maia, Estefânia, et al.
Publicado: (2014)

Special Issue on Drug–Membrane Interactions
por: Pinheiro, Marina
Publicado: (2021)

Unraveling the Role of Drug-Lipid Interactions in NSAIDs-Induced Cardiotoxicity
por: Pereira-Leite, Catarina, et al.
Publicado: (2020)

Seizures following Intoxication with a Common Antituberculosis Drug
por: Lahlou, Adnane, et al.
Publicado: (2019)

Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy
por: Granja, Andreia, et al.
Publicado: (2016)

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects
por: Mallikaarjun, Suresh, et al.
Publicado: (2016)

A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment
por: Francis, Jose, et al.
Publicado: (2021)

Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis
por: Goel, Divya
Publicado: (2014)

Maleate salts of bedaquiline
por: Zeller, Matthias, et al.
Publicado: (2021)

Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients
por: Farazi, Aliasghar, et al.
Publicado: (2014)

Risk factors associated with adverse reactions to antituberculosis drugs
por: Resende, Laíse Soares Oliveira, et al.
Publicado: (2015)

Aureolic Acid Group of Agents as Potential Antituberculosis Drugs
por: Bespyatykh, Julia, et al.
Publicado: (2020)

Epidemiology of tuberculosis and susceptibility to antituberculosis drugs in Reunion Island
por: Loukman, Moreea, et al.
Publicado: (2023)

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline
por: Ding, Yangming, et al.
Publicado: (2023)

Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
por: Vaghela, Jitendra H., et al.
Publicado: (2018)

Current Status of Amino Acid-Based Permeation Enhancers in Transdermal Drug Delivery
por: Pereira, Rui, et al.
Publicado: (2021)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Membrane Biophysics
por: Ashrafuzzaman, Mohammad, et al.
Publicado: (2013)

Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline
por: Sarathy, Jickky Palmae, et al.
Publicado: (2019)

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
por: Leibert, Eric, et al.
Publicado: (2014)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis
por: Gaida, Razia, et al.
Publicado: (2020)

Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB
por: Kambili, C., et al.
Publicado: (2022)

Association of PXR and CAR Polymorphisms and Antituberculosis Drug-Induced Hepatotoxicity
por: Wang, Yu, et al.
Publicado: (2019)

New Antituberculosis Drugs: From Clinical Trial to Programmatic Use
por: Gualano, Gina, et al.
Publicado: (2016)

Adverse drug reaction profile of daily regimen antituberculosis treatment
por: Sankar, K. N. Hari, et al.
Publicado: (2022)

Clinical impact of plasma concentrations of first-line antituberculosis drugs
por: Perumal, R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r7h3vtuu87d2m8ursk56c4j2dq